The Janssen Pharmaceutical Companies of Johnson & Johnson announced that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology's 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.
"The depth of our research at ACC this year is a testament to how our medicines help improve care for people living with cardiovascular diseases, type 2 diabetes and diabetic kidney disease," said James List, M.D., Ph.D., Global Therapeutic Area Head, Cardiovascular & Metabolism, Janssen Research & Development, LLC. "We look forward to sharing the latest evidence from our portfolio that we believe will continue to help shape clinical practice."
Janssen's cardiovascular and metabolism franchise includes XARELTO®, a direct oral anticoagulant (DOAC) with eight indications – the most of any DOAC in the class – and INVOKANA® (canagliflozin), the only type 2 diabetes (T2D) medicine proven to slow the progression of diabetic nephropathy, also known as diabetic kidney disease (DKD), and reduce the risk of hospitalization for heart failure in patients with T2D and DKD with albuminuria >300 mg/day.
Highlights from the Janssen cardiovascular and metabolism portfolio to be presented during ACC.20/WCC include:
Cardiovascular:
Metabolism:
Following is a full list of abstracts for XARELTO® and INVOKANA® to be presented during ACC.20/WCC:
Abstract No. | Title | Date/Time |
XARELTO®: Late-Breaking Presentations | ||
402-10 | Rivaroxaban for Prevention of Cardiovascular and Limb Events after Lower Extremity Revascularization: Primary Results of the VOYAGER PAD Randomized Trial | March 28 9:20 – 9:32 am CT |
403-14 | The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: Insights from the COMPASS Trial | March 28 10:45 – 10:55 am CT |
406-11 | Rivaroxaban versus Enoxaparin in Nonmajor Orthopedic Surgery (PRONOMOS) | March 29 11:00 – 11:10 am CT |
406-13 | The Benefit and Risk of Rivaroxaban Plus Aspirin in Patients with Peripheral Artery Disease after Lower Extremity Revascularization (LER) with and without Concomitant Clopidogrel: A Key Subgroup Analysis from VOYAGER PAD | March 29 11:15 – 11:25 am CT |
XARELTO®: Stroke Prevention | ||
1167-228 | Rivaroxaban versus Warfarin in African American Patients with Nonvalvular Atrial Fibrillation | March 28 12:30 – 1:15 pm CT |
XARELTO®: Vascular Protection | ||
1313-087 | Temporal Changes in Secondary Prevention and Cardiovascular Outcomes after Revascularization for Peripheral Arterial Disease in Denmark: Nationwide Cohort Study | March 29 12:30 – 1:15 pm CT |
INVOKANA®: Poster Presentations | ||
1027-05 | The Effects of Canagliflozin on Heart Failure and Cardiovascular Death by Baseline Participant Characteristics: Analysis of the CREDENCE Trial | March 28 4:00 – 4:10 pm CT |
1054-05 | Effects of Canagliflozin on Cardiovascular, Renal and Safety Outcomes by Baseline Loop Diuretic Use: Data from the CREDENCE Trial | March 29 12:45 – 12:55 pm CT |
1422-145 | Effects of Canagliflozin on Stroke in the CREDENCE Trial | March 30 9:45 – 10:30 am CT |
1422-162 | Effects of SGLT2 Inhibitors on Stroke in Type 2 Diabetes According to Baseline Kidney Function | March 30 9:45 – 10:30 am CT |
1415-72 | Canagliflozin (CANA) Reduces Cardiovascular (CV) and Renal Events Independent of Baseline Heart Failure (HF): A CREDENCE Secondary Analysis | March 30 9:45 – 10:30 am CT |
WHAT IS XARELTO® (rivaroxaban)?
XARELTO® is a prescription medicine used to:
XARELTO® is used with low dose aspirin to:
It is not known if XARELTO® is safe and effective in children.
IMPORTANT SAFETY INFORMATION
WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT XARELTO®?
XARELTO® may cause serious side effects, including:
Tell your doctor if you take any of these medicines. Ask your doctor or pharmacist if you are not sure if your medicine is one listed above.
Call your doctor or get medical help right away if you develop any of these signs or symptoms of bleeding:
If you take XARELTO® and receive spinal anesthesia or have a spinal puncture, your doctor should watch you closely for symptoms of spinal or epidural blood clots. Tell your doctor right away if you have back pain, tingling, numbness, muscle weakness (especially in your legs and feet), or loss of control of the bowels or bladder (incontinence).
XARELTO® is not for use in people with artificial heart valves.
XARELTO® is not for use in people with antiphospholipid syndrome (APS), especially with positive triple antibody testing.
Do not take XARELTO® if you:
Before taking XARELTO®, tell your doctor about all your medical conditions, including if you:
Aware of her elements, Neha writes the best articles across industries including electronics & semiconductors, automotive & transportation and food & beverages. Being from the finance background she has the ability to understand the dynamics of every industry and analyze the news updates to form insightful articles. Neha is an energetic person interested in music, travel, and entertainment. Since past 5 years, she written extensively on sectors like technology, finance and healthcare.
Smarter Decisions with Smart News
Smart Market News is committed to getting its readers the latest updates and insights on industries that help in making “smarter” business decisions. With insights and inputs from corporate decision makers, we bring you the stories of adopting innovative solutions and strategies that have been changing the world. Our editorial insights on products, solutions, companies, and adoption of best practices not only help in understanding the markets better, but also prove to be a complete package for your information needs.